Results 31 to 40 of about 164,371 (301)

Pediatric precision oncology: “better three hours too soon than a minute too late”

Frontiers in Oncology, 2023
Precision oncology is defined as the selection of an effective treatment for a cancer patient based upon genomic profiling of the patient’s tumor to identify targetable alterations.
Mark Marshall, Jennifer Ivanovich, Morgan Schmitt, Amy Helvie, Lisa Langsford, Jennifer Casterline, Michael Ferguson   +6 more
doaj   +1 more source

Biochemical Oncology for Personalized and Precision Medicine [PDF]

Egyptian Journal of Cancer and Biomedical Research, 2021
2030). Chemotherapy normo-toxicity as well as multidrug cancer cell resistance raise the debate of “Die Another Day” or “Die Another Way”. This mandates identification of chemo-preventive and/or chemo therapeutic agent(s) that can target most, if not all,
Prof.Nadia Hamdy
doaj   +1 more source

Identifying Health Information Technology Needs of Oncologists to Facilitate the Adoption of Genomic Medicine: Recommendations From the 2016 American Society of Clinical Oncology Omics and Precision Oncology Workshop

, 2020
At the ASCO Data Standards and Interoperability Summit held in May 2016, it was unanimously decided that four areas of current oncology clinical practice have serious, unmet health information technology needs. The following areas of need were identified:
Hamm, John, Yu, Peter, Routbort, Mark, Hughes, Kevin, Domdek, Susan, Clemenceau, Jean, Hess, Gregory, Chen, James, Bernstam, Elmer, Febbo, Phillip, Ambinder, Edward, Warner, Jeremy   +11 more
core   +1 more source

Italian Precision Medicine in Pediatric Oncology: Moving beyond Actionable Alterations

, 2022
Neuroblastoma (NB) is the most common extracranial solid tumor encountered in childhood. Although there has been significant improvement in the outcomes of patients with high-risk disease, the prognosis for patients with metastatic relapse or refractory ...
Bensa, Veronica, Ponzoni, Mirco, Annalisa Tondo, Serena Giglio, Garaventa, Alberto, Rossella Mura, Mirco Ponzoni, Sueva Cantalupo, Sementa, Angela Rita, Alberto Garaventa, Mario Capasso, Lasorsa, Vito Alessandro, Vito Alessandro Lasorsa, Fabio Pastorino, Veronica Bensa, Chiara Brignole, Pastorino, Fabio, Cantalupo, Sueva, Capasso, Mario, Tondo, Annalisa, Loredana Amoroso, Mura, Rossella, Angela Rita Sementa, Giglio, Serena, Brignole, Chiara, Amoroso, Loredana   +25 more
core   +1 more source

Functional Precision Oncology: The Next Frontier to Improve Glioblastoma Outcome?

, 2022
Glioblastoma remains the most malignant and intrinsically resistant brain tumour in adults. Despite intensive research over the past few decades, through which numerous potentially druggable targets have been identified, virtually all clinical trials of ...
Panovska, Dena, De Smet, Frederik, Dena Panovska, Frederik De Smet   +3 more
core   +1 more source

Microscaled proteogenomic methods for precision oncology

Nature Communications, 2020
Connecting genomics and proteomics allows the development of more efficient and specific treatments for cancer. Here, the authors develop proteogenomic methods to defining cancer signaling in-vivo starting from core needle biopsies and with application ...
Shankha Satpathy, Eric J. Jaehnig, Karsten Krug, Beom-Jun Kim, Alexander B. Saltzman, Doug W. Chan, Kimberly R. Holloway, Meenakshi Anurag, Chen Huang, Purba Singh, Ari Gao, Noel Namai, Yongchao Dou, Bo Wen, Suhas V. Vasaikar, David Mutch, Mark A. Watson, Cynthia Ma, Foluso O. Ademuyiwa, Mothaffar F. Rimawi, Rachel Schiff, Jeremy Hoog, Samuel Jacobs, Anna Malovannaya, Terry Hyslop, Karl R. Clauser, D. R. Mani, Charles M. Perou, George Miles, Bing Zhang, Michael A. Gillette, Steven A. Carr, Matthew J. Ellis   +32 more
doaj   +1 more source

Patient and Provider Perspectives on Enrollment in Precision Oncology Research: Qualitative Ethical Analysis

JMIR Cancer, 2022
BackgroundThe genomic frontier continues to revolutionize the practice of oncology. Advances in cancer biology from tumorigenesis to treatment resistance are driven by the molecular underpinnings of malignancy.
Kayte Spector-Bagdady, Madison Kent, Chris D Krenz, Collin Brummel, Paul L Swiecicki, J Chad Brenner, Andrew G Shuman   +6 more
doaj   +1 more source

Clinical Trials in Precision Oncology [PDF]

Clinical Chemistry, 2016
Abstract BACKGROUND Availability of genomic information used in the management of cancer treatment has outpaced both regulatory and reimbursement efforts. Many types of clinical trials are underway to validate the utility of emerging genome-based biomarkers for diagnostic, prognostic, and predictive ...
Mockus, Susan, Patterson, Sara E, Statz, Cara M, Bult, Carol J, Tsongalis, Gregory J   +4 more
openaire   +2 more sources

Precision Oncology: 2023 in Review

Cancer Discovery, 2023
Summary: This article presents a review of recent major advances in precision oncology and the future implications of these advances, specifying the iterative progress achieved from the end of 2022 through 2023. We discuss the different classes of precision oncology drugs and associated biomarkers as well as the ...
Murciano-Goroff, Yonina R., Suehnholz, Sarah P., Drilon, Alexander, Chakravarty, Debyani   +3 more
openaire   +2 more sources

Precision trial drawer, a computational tool to assist planning of genomics-driven trials in oncology

, 2018
Purpose Trials that accrue participants on the basis of genetic biomarkers are a powerful means of testing targeted drugs, but they are often complicated by the rarity of the biomarker-positive population.
de Maria R.
core   +2 more sources